<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25414095</article-id><article-id pub-id-type="pmc">4289382</article-id><article-id pub-id-type="publisher-id">2353</article-id><article-id pub-id-type="doi">10.1186/1745-6215-15-455</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Wordless intervention for epilepsy in learning disabilities (WIELD): study protocol for a randomized controlled feasibility trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Durand</surname><given-names>Marie-Anne</given-names></name><address><email>m.durand@herts.ac.uk</email></address><xref ref-type="aff" rid="Aff10"></xref><xref ref-type="aff" rid="Aff11"></xref></contrib><contrib contrib-type="author"><name><surname>Gates</surname><given-names>Bob</given-names></name><address><email>Bob.Gates@uwl.ac.uk</email></address><xref ref-type="aff" rid="Aff12"></xref></contrib><contrib contrib-type="author"><name><surname>Parkes</surname><given-names>Georgina</given-names></name><address><email>Georgina.Parkes@hpft.nhs.uk</email></address><xref ref-type="aff" rid="Aff13"></xref></contrib><contrib contrib-type="author"><name><surname>Zia</surname><given-names>Asif</given-names></name><address><email>Asif.Zia@hpft.nhs.uk</email></address><xref ref-type="aff" rid="Aff13"></xref></contrib><contrib contrib-type="author"><name><surname>Friedli</surname><given-names>Karin</given-names></name><address><email>k.friedli1@herts.ac.uk</email></address><xref ref-type="aff" rid="Aff10"></xref></contrib><contrib contrib-type="author"><name><surname>Barton</surname><given-names>Garry</given-names></name><address><email>G.Barton@uea.ac.uk</email></address><xref ref-type="aff" rid="Aff14"></xref></contrib><contrib contrib-type="author"><name><surname>Ring</surname><given-names>Howard</given-names></name><address><email>har28@cam.ac.uk</email></address><xref ref-type="aff" rid="Aff15"></xref></contrib><contrib contrib-type="author"><name><surname>Oostendorp</surname><given-names>Linda</given-names></name><address><email>lindaoostendorp@hotmail.com</email></address><xref ref-type="aff" rid="Aff10"></xref></contrib><contrib contrib-type="author"><name><surname>Wellsted</surname><given-names>David</given-names></name><address><email>d.m.wellsted@herts.ac.uk</email></address><xref ref-type="aff" rid="Aff10"></xref></contrib><aff id="Aff10"><label></label>Centre for Lifespan and Chronic Illness Research, Department of Psychology, School of Life and Medical Sciences, University of Hertfordshire, College Lane Campus, Hatfield, AL10 9AB UK </aff><aff id="Aff11"><label></label>The Dartmouth Institute for Health Policy and Clinical Practice, 37 Dewey Field Road, Hanover, NH 03755 USA </aff><aff id="Aff12"><label></label>University of West London, Institute for Practice, Interdisciplinary Research and Enterprise (INSPIRE), A410, St Mary’s Road, Ealing, London, W5 5RF UK </aff><aff id="Aff13"><label></label>Hertfordshire Partnership University NHS Foundation Trust, 99 Waverley Rd, St Albans, Hertfordshire AL3 5TL UK </aff><aff id="Aff14"><label></label>Norwich Medical School and Norwich Clinical Trials Unit, Faculty of Medicine and Health Sciences, Chancellor’s Drive, University of East Anglia, Norwich, NR4 7TJ UK </aff><aff id="Aff15"><label></label>Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Box 189, Cambridge, CB2 2QQ UK </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>15</volume><elocation-id>455</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>© Durand et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5406" xml_f="5416" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5427" xml_f="6120" txt_i="22" txt_f="715">Epilepsy is the most common neurological problem that affects people with learning disabilities. The high seizure frequency, resistance to treatments, associated skills deficit and co-morbidities make the management of epilepsy particularly challenging for people with learning disabilities. The Books Beyond Words booklet for epilepsy uses images to help people with learning disabilities manage their condition and improve quality of life. Our aim is to conduct a randomized controlled feasibility trial exploring key methodological, design and acceptability issues, in order to subsequently undertake a large-scale randomized controlled trial of the Books Beyond Words booklet for epilepsy.</offsets></p></sec><sec><title><offsets xml_i="6142" xml_f="6156" txt_i="717" txt_f="731">Methods/Design</offsets></title><p><offsets xml_i="6167" xml_f="7311" txt_i="732" txt_f="1876">We will use a two-arm, single-centre randomized controlled feasibility design, over a 20-month period, across five epilepsy clinics in Hertfordshire, United Kingdom. We will recruit 40 eligible adults with learning disabilities and a confirmed diagnosis of epilepsy and will randomize them to use either the Books Beyond Words booklet plus usual care (intervention group) or to receive routine information and services (control group). We will collect quantitative data about the number of eligible participants, number of recruited participants, demographic data, discontinuation rates, variability of the primary outcome measure (quality of life: Epilepsy and Learning Disabilities Quality of Life scale), seizure severity, seizure control, intervention’s patterns of use, use of other epilepsy-related information, resource use and the EQ-5D-5L health questionnaire. We will also gather qualitative data about the feasibility and acceptability of the study procedures and the Books Beyond Words booklet. Ethical approval for this study was granted on 28 April 2014, by the Wales Research Ethics Committee 5. Recruitment began on 1 July 2014.</offsets></p></sec><sec><title><offsets xml_i="7333" xml_f="7343" txt_i="1878" txt_f="1888">Discussion</offsets></title><p><offsets xml_i="7354" xml_f="7623" txt_i="1889" txt_f="2158">The outcomes of this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to determine the impact of the Books Beyond Words intervention to improve the management of epilepsy in people with learning disabilities.</offsets></p></sec><sec><title><offsets xml_i="7645" xml_f="7663" txt_i="2160" txt_f="2178">Trial registration</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://controlled-trials.com/ISRCTN80067039"><offsets xml_i="7761" xml_f="7782" txt_i="2179" txt_f="2200">http://ISRCTN80067039</offsets></ext-link><offsets xml_i="7793" xml_f="7838" txt_i="2200" txt_f="2245"> (Date of ISRCTN assignation: 23 April 2014).</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Epilepsy</kwd><kwd>Learning disability</kwd><kwd>Intervention</kwd><kwd>Feasibility trial</kwd><kwd>Clinical protocol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="8257" xml_f="8267" txt_i="2254" txt_f="2264">Background</offsets></title><sec id="Sec2"><title><offsets xml_i="8297" xml_f="8306" txt_i="2265" txt_f="2274">Rationale</offsets></title><p><offsets xml_i="8317" xml_f="8618" txt_i="2275" txt_f="2576">People with learning disabilities experience a disproportionate burden of ill health and are affected by twice the number of health issues prevailing in the general population: higher incidence of long-term conditions and health risks, poorer health outcomes and an increased risk of premature death [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="8650" xml_f="8651" txt_i="2576" txt_f="2577">1</offsets></xref><offsets xml_i="8658" xml_f="8659" txt_i="2577" txt_f="2578">–</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="8691" xml_f="8692" txt_i="2578" txt_f="2579">4</offsets></xref><offsets xml_i="8699" xml_f="8851" txt_i="2579" txt_f="2731">]. Epilepsy is one of many long-term conditions affecting people with learning disabilities that burdens their lives and hinders their quality of life [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="8883" xml_f="8884" txt_i="2731" txt_f="2732">5</offsets></xref><offsets xml_i="8891" xml_f="9028" txt_i="2732" txt_f="2869">]. It is considered the most common neurological disorder in people with learning disabilities, with a reported prevalence of 16 to 44% [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="9060" xml_f="9061" txt_i="2869" txt_f="2870">2</offsets></xref><offsets xml_i="9068" xml_f="9070" txt_i="2870" txt_f="2872">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="9102" xml_f="9103" txt_i="2872" txt_f="2873">5</offsets></xref><offsets xml_i="9110" xml_f="9111" txt_i="2873" txt_f="2874">–</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="9143" xml_f="9144" txt_i="2874" txt_f="2875">8</offsets></xref><offsets xml_i="9151" xml_f="9204" txt_i="2875" txt_f="2928">], compared to 0.4% to 1% in the general population [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9236" xml_f="9237" txt_i="2928" txt_f="2929">9</offsets></xref><offsets xml_i="9244" xml_f="9246" txt_i="2929" txt_f="2931">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9279" xml_f="9281" txt_i="2931" txt_f="2933">10</offsets></xref><offsets xml_i="9288" xml_f="9290" txt_i="2933" txt_f="2935">].</offsets></p><p><offsets xml_i="9297" xml_f="9616" txt_i="2936" txt_f="3255">The clinical management of epilepsy in people with learning disabilities is complex, due to both the clinical characteristics of the condition, as well as physical and cognitive impairments affecting them. Seizures are frequent, atypical and often severe. Approximately 70% of all seizures are refractory to treatment [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9649" xml_f="9651" txt_i="3255" txt_f="3257">11</offsets></xref><offsets xml_i="9658" xml_f="9659" txt_i="3257" txt_f="3258">–</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9692" xml_f="9694" txt_i="3258" txt_f="3260">14</offsets></xref><offsets xml_i="9701" xml_f="9893" txt_i="3260" txt_f="3452">]. Seizures are less well controlled than in the general population of people with epilepsy, and may be accompanied by co-morbid health, mental health, sensory-motor and communication issues [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="9926" xml_f="9928" txt_i="3452" txt_f="3454">15</offsets></xref><offsets xml_i="9935" xml_f="9936" txt_i="3454" txt_f="3455">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="9969" xml_f="9971" txt_i="3455" txt_f="3457">17</offsets></xref><offsets xml_i="9978" xml_f="10105" txt_i="3457" txt_f="3584">]. Poorly controlled epilepsy can severely affect social relationships, work, daily activities, quality of life and mortality [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="10138" xml_f="10140" txt_i="3584" txt_f="3586">18</offsets></xref><offsets xml_i="10147" xml_f="10148" txt_i="3586" txt_f="3587">–</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="10181" xml_f="10183" txt_i="3587" txt_f="3589">20</offsets></xref><offsets xml_i="10190" xml_f="10370" txt_i="3589" txt_f="3769">]. As a result, young people and adults with learning disabilities and epilepsy face higher risks of premature and avoidable death related to epilepsy than the general population [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="10403" xml_f="10405" txt_i="3769" txt_f="3771">21</offsets></xref><offsets xml_i="10412" xml_f="10534" txt_i="3771" txt_f="3893">]. In addition, research shows that poorly controlled seizures and seizure frequency are associated with increased costs [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="10567" xml_f="10569" txt_i="3893" txt_f="3895">22</offsets></xref><offsets xml_i="10576" xml_f="10590" txt_i="3895" txt_f="3909">]. Pennington </offsets><italic><offsets xml_i="10598" xml_f="10604" txt_i="3909" txt_f="3915">et al.</offsets></italic><offsets xml_i="10613" xml_f="10703" txt_i="3915" txt_f="4005"> recently demonstrated increased costs in people with epilepsy and learning disabilities [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="10736" xml_f="10738" txt_i="4005" txt_f="4007">23</offsets></xref><offsets xml_i="10745" xml_f="10852" txt_i="4007" txt_f="4114">], with a total estimated cost per patient, per annum, of £64,000 (including accommodation and basic care).</offsets></p><p><offsets xml_i="10859" xml_f="11334" txt_i="4115" txt_f="4590">Managing long-term conditions is challenging for all patients, irrespective of their abilities and co-morbidities. However, it is even more complex for those with learning disabilities, who may not have the knowledge, skills and support required to assess potential risks and cope with recurring seizures, prescribed medications and regular doctor appointments. Research suggests that access to specialist services is poor for people with epilepsy and learning disabilities [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="11367" xml_f="11369" txt_i="4590" txt_f="4592">24</offsets></xref><offsets xml_i="11376" xml_f="11561" txt_i="4592" txt_f="4777">]. For carers and families who are not trained in supporting self-management, caring for adults with ‘dual disabilities’ can be extremely challenging and increase the caregiver burden [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="11593" xml_f="11594" txt_i="4777" txt_f="4778">5</offsets></xref><offsets xml_i="11601" xml_f="11953" txt_i="4778" txt_f="5130">]. Despite its high incidence, little is known about the management of epilepsy in people with learning disabilities, and those who support them. Research suggests that people with learning disabilities and epilepsy lack skills training adapted to their needs and intellectual abilities, and often fail to adequately manage and control their epilepsy [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="11986" xml_f="11988" txt_i="5130" txt_f="5132">20</offsets></xref><offsets xml_i="11995" xml_f="12216" txt_i="5132" txt_f="5353">]. The standard of care offered to people with learning disabilities and epilepsy is significantly poorer than in the general population, as is the case for most disease areas affecting people with learning disabilities [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="12249" xml_f="12251" txt_i="5353" txt_f="5355">24</offsets></xref><offsets xml_i="12258" xml_f="12260" txt_i="5355" txt_f="5357">, </offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="12293" xml_f="12295" txt_i="5357" txt_f="5359">25</offsets></xref><offsets xml_i="12302" xml_f="12304" txt_i="5359" txt_f="5361">].</offsets></p><p><offsets xml_i="12311" xml_f="12704" txt_i="5362" txt_f="5755">Guidelines from the National Institute for Health and Care Excellence (NICE) state that patients with epilepsy and learning disabilities: ‘should be empowered to manage their condition as well as possible, and should receive appropriate information and education about all aspects of epilepsy […] accessible to people with additional needs such as physical, sensory or learning disabilities’ [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="12737" xml_f="12739" txt_i="5755" txt_f="5757">26</offsets></xref><offsets xml_i="12746" xml_f="12753" txt_i="5757" txt_f="5764">]; p.9.</offsets></p><p><offsets xml_i="12760" xml_f="12791" txt_i="5765" txt_f="5796">The Books Beyond Words booklet </offsets><italic><offsets xml_i="12799" xml_f="12823" txt_i="5796" txt_f="5820">Getting on with Epilepsy</offsets></italic><offsets xml_i="12832" xml_f="13685" txt_i="5820" txt_f="6673"> has been designed to help people with learning disabilities and epilepsy understand and manage their illness through images that have been tested with people with mild to severe learning disabilities. The intervention is based on the assumption that people with learning disabilities who cannot read and have limited communication abilities are visually literate. Although the success and impact of the Books Beyond Words booklets (over 30 available) have been recognized by several awards and collaborations with established patient organizations, they have not as yet been formally evaluated in controlled settings or routinely adopted in the United Kingdom National Health Service (NHS). The lack of conclusive data on the effectiveness of educational interventions for people with epilepsy and learning disabilities warrants further investigation [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="13718" xml_f="13720" txt_i="6673" txt_f="6675">24</offsets></xref><offsets xml_i="13727" xml_f="13729" txt_i="6675" txt_f="6677">, </offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="13762" xml_f="13764" txt_i="6677" txt_f="6679">26</offsets></xref><offsets xml_i="13771" xml_f="13773" txt_i="6679" txt_f="6681">].</offsets></p></sec><sec id="Sec3"><title><offsets xml_i="13805" xml_f="13808" txt_i="6683" txt_f="6686">Aim</offsets></title><p><offsets xml_i="13819" xml_f="14122" txt_i="6687" txt_f="6990">We aim to conduct a randomized controlled feasibility trial exploring key methodological, design and acceptability issues, in order to subsequently undertake a large-scale randomized controlled trial of the Books Beyond Words booklet as an intervention for epilepsy in adults with learning disabilities.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="14154" xml_f="14164" txt_i="6992" txt_f="7002">Objectives</offsets></title><p><offsets xml_i="14175" xml_f="14197" txt_i="7003" txt_f="7025">Our objectives are to:</offsets><list list-type="order"><list-item><p><offsets xml_i="14235" xml_f="14392" txt_i="7025" txt_f="7182">Assess the feasibility of undertaking a randomized controlled trial of the Books Beyond Words intervention for epilepsy in people with learning disabilities.</offsets></p></list-item><list-item><p><offsets xml_i="14422" xml_f="14591" txt_i="7183" txt_f="7352">To explore the feasibility of collecting resource use and quality of life data so as to inform the design of the health economics component of a future definitive trial.</offsets></p></list-item><list-item><p><offsets xml_i="14621" xml_f="14756" txt_i="7353" txt_f="7488">Assess the study procedures’ and intervention’s acceptability among adults with learning disabilities, carers and health professionals.</offsets></p></list-item></list></p></sec></sec><sec id="Sec5"><title><offsets xml_i="14817" xml_f="14831" txt_i="7492" txt_f="7506">Methods/Design</offsets></title><sec id="Sec6"><title><offsets xml_i="14861" xml_f="14885" txt_i="7507" txt_f="7531">Study design and setting</offsets></title><p><offsets xml_i="14896" xml_f="15330" txt_i="7532" txt_f="7966">We will use a two-arm, single-centre design and will conduct the study over a 20-month period at Hertfordshire Partnership University NHS Foundation Trust, United Kingdom. The trust runs five epilepsy clinics, managing 196 adults with learning disabilities and epilepsy. The patients are seen on average once a month. We will randomly allocate eligible participants to an intervention arm (provision of the Books Beyond Words booklet </offsets><italic><offsets xml_i="15338" xml_f="15362" txt_i="7966" txt_f="7990">Getting on with Epilepsy</offsets></italic><offsets xml_i="15371" xml_f="15471" txt_i="7990" txt_f="8090">) and control arm (routine information and services), and will recruit participants over six months.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="15503" xml_f="15515" txt_i="8092" txt_f="8104">Participants</offsets></title><p><offsets xml_i="15526" xml_f="15773" txt_i="8105" txt_f="8352">Eligible participants will be identified by the consultant psychiatrists who run the epilepsy clinics. Each psychiatrist will compile a log of potentially eligible patients from existing records and from new referrals using the following criteria.</offsets></p><sec id="Sec8"><title><offsets xml_i="15799" xml_f="15817" txt_i="8353" txt_f="8371">Inclusion criteria</offsets></title><p><offsets xml_i="15828" xml_f="15881" txt_i="8372" txt_f="8425">The inclusion criteria for this study are as follows:</offsets><list list-type="order"><list-item><p><offsets xml_i="15919" xml_f="15966" txt_i="8425" txt_f="8472">Male and female patients, over 18 years of age.</offsets></p></list-item><list-item><p><offsets xml_i="15996" xml_f="16117" txt_i="8473" txt_f="8594">A confirmed clinical diagnosis of epilepsy (according to medical notes) and at least one seizure over the past 12 months.</offsets></p></list-item><list-item><p><offsets xml_i="16147" xml_f="16298" txt_i="8595" txt_f="8746">A confirmed clinical diagnosis of a learning disability (significantly below-average general intellectual functioning, and an IQ below or equal to 70).</offsets></p></list-item><list-item><p><offsets xml_i="16328" xml_f="16476" txt_i="8747" txt_f="8895">Meaningful communication that enables the patient to tell or follow the Books Beyond Words story, as judged by the carer and/or health professional.</offsets></p></list-item><list-item><p><offsets xml_i="16506" xml_f="16611" txt_i="8896" txt_f="9001">The carer is sufficiently proficient in English to read and complete the questionnaires with the patient.</offsets></p></list-item></list></p></sec><sec id="Sec9"><title><offsets xml_i="16666" xml_f="16684" txt_i="9004" txt_f="9022">Exclusion criteria</offsets></title><p><offsets xml_i="16695" xml_f="16748" txt_i="9023" txt_f="9076">The exclusion criteria for this study are as follows:</offsets><list list-type="order"><list-item><p><offsets xml_i="16786" xml_f="16804" txt_i="9076" txt_f="9094">Vision impairment.</offsets></p></list-item><list-item><p><offsets xml_i="16834" xml_f="16866" txt_i="9095" txt_f="9127">Confirmed diagnosis of dementia.</offsets></p></list-item><list-item><p><offsets xml_i="16896" xml_f="16972" txt_i="9128" txt_f="9204">Have used the Books Beyond Words booklet for epilepsy in the past 12 months.</offsets></p></list-item></list></p></sec></sec></sec><sec id="Sec10"><title><offsets xml_i="17040" xml_f="17047" txt_i="9209" txt_f="9216">Consent</offsets></title><p><offsets xml_i="17058" xml_f="17338" txt_i="9217" txt_f="9497">Each consultant psychiatrist at the participating epilepsy clinics will send an invitation letter and two information sheets to the carers of all eligible patients with learning disabilities and epilepsy registered at the clinics. In accordance with the Mental Capacity Act 2005 [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="17371" xml_f="17373" txt_i="9497" txt_f="9499">27</offsets></xref><offsets xml_i="17380" xml_f="17996" txt_i="9499" txt_f="10115">], an easy-read information sheet and invitation letter will be intended for the patient and another information sheet for the carer. In the information sheet, carers will be asked to encourage patients who have the capacity to read and understand (or to be read to and understand) the easy-read information sheet to do so. For patients who lack the mental capacity to understand the information sheet, consent will be obtained from the patient’s carer. It will be the carer’s role to use what they know of the patient’s wishes and feelings about research to decide whether they would like to take part in the study.</offsets></p><p><offsets xml_i="18003" xml_f="18615" txt_i="10116" txt_f="10728">After a week, the research nurse will invite carers and patients by phone, to attend a meeting at the epilepsy clinic. During this appointment, the research nurse will review the patient information sheets with both the patient and the carer, and will take consent from the patient, with the carer’s involvement and advice, using an easy-read consent form. For patients who lack the capacity to consent, the research nurse will use a consultee declaration form, which will be completed and signed by the carer. The research nurse will also inform the patient’s GP of their participation in the feasibility trial.</offsets></p><sec id="Sec11"><title><offsets xml_i="18642" xml_f="18655" txt_i="10729" txt_f="10742">Randomization</offsets></title><p><offsets xml_i="18666" xml_f="19700" txt_i="10743" txt_f="11777">During the initial appointment with the research nurse at the epilepsy clinic, and after consent has been taken, the carer will complete the baseline questionnaire. Randomization will be managed by the Norwich Clinical Trials Unit (NCTU). Once consent is obtained and the baseline data registered, the research nurse will allocate the patient to the intervention or control arm, as instructed by the randomization website. All authorized users, including the research nurse, will login using their unique username and password to a secure website to randomize each participant. The results will be stored in a study database on the Norwich Clinical Trials Unit (NCTU) secure server at the University of East Anglia (no user identifiable data will be stored in the randomization database). Web traffic will be encrypted using standard secure sockets layer technology. The randomization (1:1 allocation ratio) will be ‘blocked’ into groups of six codes to reduce the imbalance of control and intervention group participants at any time.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="19733" xml_f="19751" txt_i="11779" txt_f="11797">Intervention group</offsets></title><p><offsets xml_i="19762" xml_f="19793" txt_i="11798" txt_f="11829">The Books Beyond Words booklet </offsets><italic><offsets xml_i="19801" xml_f="19825" txt_i="11829" txt_f="11853">Getting on with Epilepsy</offsets></italic><offsets xml_i="19834" xml_f="20017" txt_i="11853" txt_f="12036"> uses pictures to tell the story of a young man with learning disabilities and epilepsy who progressively learns how to better manage his condition and recurrent seizures (see Figure </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="20049" xml_f="20050" txt_i="12036" txt_f="12037">1</offsets></xref><offsets xml_i="20057" xml_f="20860" txt_i="12037" txt_f="12840">). The intervention aims to improve seizure control, reduce the risk of falls and seizure-related injuries and improve quality of life. It also aims to illustrate best practice and promote access to relevant services. The Books Beyond Words booklet for epilepsy was developed over an 18-month period, by an editorial team of consultants in psychiatry and neurodevelopmental psychiatry, a speech and language therapist and an illustrator. They were supported by an advisory group of medical experts in the field of epilepsy and learning disabilities, by adults with learning disabilities and their carers, voluntary organizations and advocacy groups. Several iterations were developed and tested with a wide group of stakeholders, including adults with mild to severe learning disabilities and epilepsy [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="20893" xml_f="20895" txt_i="12840" txt_f="12842">28</offsets></xref><offsets xml_i="20902" xml_f="20904" txt_i="12842" txt_f="12844">].</offsets><fig id="Fig1"><label><offsets xml_i="20926" xml_f="20934" txt_i="12844" txt_f="12852">Figure 1</offsets></label><caption><p><offsets xml_i="20954" xml_f="20955" txt_i="12852" txt_f="12853">
</offsets><bold><offsets xml_i="20961" xml_f="20997" txt_i="12853" txt_f="12889">The Books Beyond Words intervention.</offsets></bold><offsets xml_i="21004" xml_f="21005" txt_i="12889" txt_f="12890">
</offsets></p></caption><graphic xlink:href="13063_2014_2353_Fig1_HTML" id="d30e657"></graphic></fig></p><sec id="Sec13"><title><offsets xml_i="21123" xml_f="21175" txt_i="12892" txt_f="12944">How the Books Beyond Words intervention will be used</offsets></title><p><offsets xml_i="21186" xml_f="22356" txt_i="12945" txt_f="14115">After giving consent and completing the baseline questionnaires, patients in the intervention condition will use the booklet with the research nurse and carer, in a quiet room at the epilepsy clinic. The nurse will go through the booklet with each patient at their own pace. Health professionals and carers can create their own story with the patient or use the story provided at the end of the booklet. The booklet contains instructions for use and a list of useful resources and services. The research nurse will show the first picture of the booklet to the person with learning disabilities, who should be encouraged to hold the book and turn the pages at their own pace. Depending on the patient’s communication abilities and reactions, it is advised that the research nurse will prompt them to say what is happening, whether this has happened to them before, and how they feel about it. We anticipate that it may take up to one hour to go through the booklet. If the intervention cannot be explored in one sitting, the research nurse will arrange a further appointment. The patient will also be given a copy to take home and explore with the carer and/or relatives.</offsets></p><p><offsets xml_i="22363" xml_f="23162" txt_i="14116" txt_f="14915">It is recommended that the patient is given the opportunity to use the book at least twice more at home over the study duration. The research nurse will call each carer two weeks after randomization to remind them that the patient should be given opportunities to use the booklet at least twice more. Use of the book at home with the carer or other relatives will be monitored as part of the follow-up assessments. The carers will not receive any formal training in using the booklet, but will be able to watch an online video and training slides explaining how to use the book with the person they care for. A link to the training video and slides will be provided by the nurse at the end of the initial meeting. The research nurse will receive a half-day training course in using the intervention.</offsets></p></sec></sec><sec id="Sec14"><title><offsets xml_i="23201" xml_f="23214" txt_i="14918" txt_f="14931">Control group</offsets></title><p><offsets xml_i="23225" xml_f="23645" txt_i="14932" txt_f="15352">Participants in the control group will receive routine information and services. The use of a picture book, such as the Books Beyond Words intervention or other educational package, will not be part of the routine consultation. After the study has terminated, patients in the control condition will be provided with a Books Beyond Words booklet to use with the epilepsy nurse specialist, the consultant and/or the carer.</offsets></p></sec><sec id="Sec15"><title><offsets xml_i="23678" xml_f="23694" txt_i="15354" txt_f="15370">Outcome measures</offsets></title><p><offsets xml_i="23705" xml_f="23829" txt_i="15371" txt_f="15495">Each patient will be assessed at baseline (T0), and at four (T1), 12 (T2) and 20 (T3) weeks after randomization (see Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="23861" xml_f="23862" txt_i="15495" txt_f="15496">2</offsets></xref><offsets xml_i="23869" xml_f="23972" txt_i="15496" txt_f="15599">.). We will measure the following outcomes for both groups except where specified otherwise (see Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="24006" xml_f="24007" txt_i="15599" txt_f="15600">1</offsets></xref><offsets xml_i="24014" xml_f="24016" txt_i="15600" txt_f="15602">).</offsets><fig id="Fig2"><label><offsets xml_i="24038" xml_f="24046" txt_i="15602" txt_f="15610">Figure 2</offsets></label><caption><p><offsets xml_i="24066" xml_f="24067" txt_i="15610" txt_f="15611">
</offsets><bold><offsets xml_i="24073" xml_f="24143" txt_i="15611" txt_f="15681">Consolidated Standards of Reporting Trials (CONSORT) study flow-chart.</offsets></bold><offsets xml_i="24150" xml_f="24151" txt_i="15681" txt_f="15682">
</offsets></p></caption><graphic xlink:href="13063_2014_2353_Fig2_HTML" id="d30e692"></graphic></fig></p><table-wrap id="Tab1"><label><offsets xml_i="24275" xml_f="24282" txt_i="15684" txt_f="15691">Table 1</offsets></label><caption><p><offsets xml_i="24302" xml_f="24303" txt_i="15691" txt_f="15692">
</offsets><bold><offsets xml_i="24309" xml_f="24353" txt_i="15692" txt_f="15736">Study procedures according to study schedule</offsets></bold><offsets xml_i="24360" xml_f="24361" txt_i="15736" txt_f="15737">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="24427" xml_f="24443" txt_i="15738" txt_f="15754">Study procedures</offsets></th><th colspan="5"><offsets xml_i="24464" xml_f="24476" txt_i="15754" txt_f="15766">Study period</offsets></th></tr><tr><th></th><th><offsets xml_i="24503" xml_f="24513" txt_i="15766" txt_f="15776">Enrollment</offsets></th><th><offsets xml_i="24522" xml_f="24535" txt_i="15776" txt_f="15789">Randomization</offsets></th><th colspan="3"><offsets xml_i="24556" xml_f="24574" txt_i="15789" txt_f="15807">Post-randomization</offsets></th></tr><tr><th></th><th></th><th><offsets xml_i="24610" xml_f="24612" txt_i="15807" txt_f="15809">T0</offsets></th><th><offsets xml_i="24621" xml_f="24630" txt_i="15809" txt_f="15818">T1 week 4</offsets></th><th><offsets xml_i="24639" xml_f="24649" txt_i="15818" txt_f="15828">T2 week 12</offsets></th><th><offsets xml_i="24658" xml_f="24668" txt_i="15828" txt_f="15838">T3 week 20</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="24701" xml_f="24702" txt_i="15838" txt_f="15839">
</offsets><bold><offsets xml_i="24708" xml_f="24726" txt_i="15839" txt_f="15857">Eligibility screen</offsets></bold><offsets xml_i="24733" xml_f="24734" txt_i="15857" txt_f="15858">
</offsets></td><td align="center"><offsets xml_i="24758" xml_f="24759" txt_i="15859" txt_f="15860">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="24873" xml_f="24874" txt_i="15865" txt_f="15866">
</offsets><bold><offsets xml_i="24880" xml_f="24896" txt_i="15866" txt_f="15882">Informed consent</offsets></bold><offsets xml_i="24903" xml_f="24904" txt_i="15882" txt_f="15883">
</offsets></td><td align="center"><offsets xml_i="24928" xml_f="24929" txt_i="15884" txt_f="15885">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="25043" xml_f="25044" txt_i="15890" txt_f="15891">
</offsets><bold><offsets xml_i="25050" xml_f="25060" txt_i="15891" txt_f="15901">Allocation</offsets></bold><offsets xml_i="25067" xml_f="25068" txt_i="15901" txt_f="15902">
</offsets></td><td align="center"></td><td align="center"><offsets xml_i="25116" xml_f="25117" txt_i="15904" txt_f="15905">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="25207" xml_f="25208" txt_i="15909" txt_f="15910">
</offsets><bold><offsets xml_i="25214" xml_f="25226" txt_i="15910" txt_f="15922">Intervention</offsets></bold><offsets xml_i="25233" xml_f="25234" txt_i="15922" txt_f="15923">
</offsets></td><td align="center"></td><td align="center"><offsets xml_i="25282" xml_f="25283" txt_i="15925" txt_f="15926">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="25373" xml_f="25374" txt_i="15930" txt_f="15931">
</offsets><bold><offsets xml_i="25380" xml_f="25400" txt_i="15931" txt_f="15951">Rates of recruitment</offsets></bold><offsets xml_i="25407" xml_f="25408" txt_i="15951" txt_f="15952">
</offsets></td><td align="center"></td><td align="center"><offsets xml_i="25456" xml_f="25457" txt_i="15954" txt_f="15955">X</offsets></td><td align="center"><offsets xml_i="25481" xml_f="25482" txt_i="15956" txt_f="15957">X</offsets></td><td align="center"><offsets xml_i="25506" xml_f="25507" txt_i="15958" txt_f="15959">X</offsets></td><td align="center"><offsets xml_i="25531" xml_f="25532" txt_i="15960" txt_f="15961">X</offsets></td></tr><tr><td><offsets xml_i="25550" xml_f="25551" txt_i="15962" txt_f="15963">
</offsets><bold><offsets xml_i="25557" xml_f="25572" txt_i="15963" txt_f="15978">Quality of life</offsets></bold><offsets xml_i="25579" xml_f="25647" txt_i="15978" txt_f="16046"> (Epilepsy and Learning Disabilities Quality of Life, ELDQOL. scale)</offsets></td><td align="center"></td><td align="center"><offsets xml_i="25695" xml_f="25696" txt_i="16048" txt_f="16049">X</offsets></td><td align="center"><offsets xml_i="25720" xml_f="25721" txt_i="16050" txt_f="16051">X</offsets></td><td align="center"><offsets xml_i="25745" xml_f="25746" txt_i="16052" txt_f="16053">X</offsets></td><td align="center"><offsets xml_i="25770" xml_f="25771" txt_i="16054" txt_f="16055">X</offsets></td></tr><tr><td><offsets xml_i="25789" xml_f="25790" txt_i="16056" txt_f="16057">
</offsets><bold><offsets xml_i="25796" xml_f="25812" txt_i="16057" txt_f="16073">Demographic data</offsets></bold><offsets xml_i="25819" xml_f="25820" txt_i="16073" txt_f="16074">
</offsets></td><td align="center"></td><td align="center"><offsets xml_i="25868" xml_f="25869" txt_i="16076" txt_f="16077">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="25959" xml_f="25960" txt_i="16081" txt_f="16082">
</offsets><bold><offsets xml_i="25966" xml_f="25982" txt_i="16082" txt_f="16098">Seizure severity</offsets></bold><offsets xml_i="25989" xml_f="26027" txt_i="16098" txt_f="16136"> (using ELDQOL Seizure Severity Scale)</offsets></td><td align="center"></td><td align="center"><offsets xml_i="26075" xml_f="26076" txt_i="16138" txt_f="16139">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td><offsets xml_i="26166" xml_f="26167" txt_i="16143" txt_f="16144">
</offsets><bold><offsets xml_i="26173" xml_f="26188" txt_i="16144" txt_f="16159">Seizure control</offsets></bold><offsets xml_i="26195" xml_f="26209" txt_i="16159" txt_f="16173"> (diary cards)</offsets></td><td align="center"></td><td align="center"><offsets xml_i="26257" xml_f="26258" txt_i="16175" txt_f="16176">X</offsets></td><td align="center"><offsets xml_i="26282" xml_f="26283" txt_i="16177" txt_f="16178">X</offsets></td><td align="center"><offsets xml_i="26307" xml_f="26308" txt_i="16179" txt_f="16180">X</offsets></td><td align="center"><offsets xml_i="26332" xml_f="26333" txt_i="16181" txt_f="16182">X</offsets></td></tr><tr><td><offsets xml_i="26351" xml_f="26352" txt_i="16183" txt_f="16184">
</offsets><bold><offsets xml_i="26358" xml_f="26387" txt_i="16184" txt_f="16213">Feasibility and acceptability</offsets></bold><offsets xml_i="26394" xml_f="26419" txt_i="16213" txt_f="16238"> (qualitative interviews)</offsets></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"><offsets xml_i="26539" xml_f="26540" txt_i="16243" txt_f="16244">X</offsets></td></tr><tr><td><offsets xml_i="26558" xml_f="26559" txt_i="16245" txt_f="16246">
</offsets><bold><offsets xml_i="26565" xml_f="26577" txt_i="16246" txt_f="16258">Resource use</offsets></bold><offsets xml_i="26584" xml_f="26585" txt_i="16258" txt_f="16259">
</offsets></td><td align="center"></td><td align="center"><offsets xml_i="26633" xml_f="26634" txt_i="16261" txt_f="16262">X</offsets></td><td align="center"></td><td align="center"></td><td align="center"><offsets xml_i="26706" xml_f="26707" txt_i="16265" txt_f="16266">X</offsets></td></tr><tr><td><offsets xml_i="26725" xml_f="26726" txt_i="16267" txt_f="16268">
</offsets><bold><offsets xml_i="26732" xml_f="26747" txt_i="16268" txt_f="16283">Quality of life</offsets></bold><offsets xml_i="26754" xml_f="26771" txt_i="16283" txt_f="16300"> (EQ-5D-5L scale)</offsets></td><td align="center"></td><td align="center"><offsets xml_i="26819" xml_f="26820" txt_i="16302" txt_f="16303">X</offsets></td><td align="center"><offsets xml_i="26844" xml_f="26845" txt_i="16304" txt_f="16305">X</offsets></td><td align="center"><offsets xml_i="26869" xml_f="26870" txt_i="16306" txt_f="16307">X</offsets></td><td align="center"><offsets xml_i="26894" xml_f="26895" txt_i="16308" txt_f="16309">X</offsets></td></tr></tbody></table></table-wrap><sec id="Sec16"><title><offsets xml_i="26957" xml_f="26980" txt_i="16310" txt_f="16333">Quantitative assessment</offsets></title><p><offsets xml_i="26991" xml_f="27046" txt_i="16334" txt_f="16389">The quantitative assessment will examine the following:</offsets><list list-type="order"><list-item><p><offsets xml_i="27084" xml_f="27144" txt_i="16389" txt_f="16449">Number of eligible patients identified and number recruited.</offsets></p></list-item><list-item><p><offsets xml_i="27174" xml_f="27303" txt_i="16450" txt_f="16579">Variability of the primary outcome quality of life, using the Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="27336" xml_f="27338" txt_i="16579" txt_f="16581">29</offsets></xref><offsets xml_i="27345" xml_f="27347" txt_i="16581" txt_f="16583">, </offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="27380" xml_f="27382" txt_i="16583" txt_f="16585">30</offsets></xref><offsets xml_i="27389" xml_f="27482" txt_i="16585" txt_f="16678">]. The ELDQOL consists of four subscales: behaviour, seizure severity, mood and side effects.</offsets></p></list-item><list-item><p><offsets xml_i="27512" xml_f="27591" txt_i="16679" txt_f="16758">Seizure control as a secondary outcome measure, assessed using a seizure diary.</offsets></p></list-item><list-item><p><offsets xml_i="27621" xml_f="27735" txt_i="16759" txt_f="16873">Seizure severity as a secondary outcome measure, assessed using the seizure severity subscale of the ELDQOL scale.</offsets></p></list-item><list-item><p><offsets xml_i="27765" xml_f="27816" txt_i="16874" txt_f="16925">Discontinuation rates across both arms and reasons.</offsets></p></list-item><list-item><p><offsets xml_i="27846" xml_f="27926" txt_i="16926" txt_f="17006">Patterns of use of the Books Beyond Words booklet (for intervention group only).</offsets></p></list-item><list-item><p><offsets xml_i="27956" xml_f="27998" txt_i="17007" txt_f="17049">Use of other epilepsy-related information.</offsets></p></list-item><list-item><p><offsets xml_i="28028" xml_f="28153" txt_i="17050" txt_f="17175">Resource use and health-related quality of life using a context-specific resource use questionnaire and the EQ-5D-5 L scale [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="28186" xml_f="28188" txt_i="17175" txt_f="17177">31</offsets></xref><offsets xml_i="28195" xml_f="28197" txt_i="17177" txt_f="17179">].</offsets></p></list-item><list-item><p><offsets xml_i="28227" xml_f="28404" txt_i="17180" txt_f="17357">Demographic data: age, sex, ethnicity, and living circumstances of the participant, information about the type of care provided by the carer and relationship to the participant.</offsets></p></list-item></list></p></sec><sec id="Sec17"><title><offsets xml_i="28460" xml_f="28482" txt_i="17360" txt_f="17382">Qualitative assessment</offsets></title><p><offsets xml_i="28493" xml_f="29231" txt_i="17383" txt_f="18121">We will conduct semi-structured qualitative interviews at 20 weeks post-randomization, with a random sample of 15 patients and carers (or until data saturation), selected from both control and intervention groups, as well as all health professionals involved in the feasibility trial (n = 9). The semi-structured interviews will explore the feasibility and acceptability of the recruitment procedures (such as allocation, randomization and potential weaknesses of the design), use and perceived usefulness of existing resources and services, information and self-management support needs, perceived acceptability of the intervention and perceived barriers and facilitators to the use and dissemination of the intervention in routine care.</offsets></p></sec></sec><sec id="Sec18"><title><offsets xml_i="29270" xml_f="29300" txt_i="18124" txt_f="18154">Data collection and management</offsets></title><p><offsets xml_i="29311" xml_f="29978" txt_i="18155" txt_f="18822">Data will be collected at baseline, four, 12 and 20 weeks post-randomization using a questionnaire and seizure diary completed by the carer, with the patient’s involvement whenever possible. The baseline questionnaire will be completed at the initial meeting with the research nurse. The follow-up questionnaires will be sent to the carer in the post and returned in a prepaid envelope. A research fellow will follow-up on patients and carers using the telephone at four, 12 and 20 weeks post-randomization to encourage the return of the questionnaires. A random sample of participants will also be invited to take part in an interview at 20 weeks post-randomization.</offsets></p><p><offsets xml_i="29985" xml_f="30364" txt_i="18823" txt_f="19202">Data management will be provided by NRTU. The web-based data entry system will be built using Microsoft SQL Server tools. It will comply with the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (GCP), and will be restricted to authorized study team members and NRTU staff.</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="30397" xml_f="30410" txt_i="19204" txt_f="19217">Data analysis</offsets></title><sec id="Sec20"><title><offsets xml_i="30441" xml_f="30458" txt_i="19218" txt_f="19235">Quantitative data</offsets></title><p><offsets xml_i="30469" xml_f="30606" txt_i="19236" txt_f="19373">The analysis primarily aims to determine the feasibility of undertaking a full-scale randomized controlled trial and will seek to assess:</offsets><list list-type="order"><list-item><p><offsets xml_i="30644" xml_f="30797" txt_i="19373" txt_f="19526">The number and demographics of eligible patients identified, screened, consented and randomized to each arm, and the relative performance in each clinic.</offsets></p></list-item><list-item><p><offsets xml_i="30827" xml_f="31018" txt_i="19527" txt_f="19718">The demographics of patients who are excluded from the trial, reasons for exclusion and estimation of the proportion of eligible patients approached who agree to enter and complete the trial.</offsets></p></list-item><list-item><p><offsets xml_i="31048" xml_f="31160" txt_i="19719" txt_f="19831">The proportion of completed study measures in each arm, measured from baseline to the last follow-up assessment.</offsets></p></list-item><list-item><p><offsets xml_i="31190" xml_f="31301" txt_i="19832" txt_f="19943">The proportion of patients withdrawing from the study, measured from baseline to the last follow-up assessment.</offsets></p></list-item><list-item><p><offsets xml_i="31331" xml_f="31426" txt_i="19944" txt_f="20039">The variation in the primary outcome measure that will be used, following Cocks and Torgerson [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="31459" xml_f="31461" txt_i="20039" txt_f="20041">32</offsets></xref><offsets xml_i="31468" xml_f="31589" txt_i="20041" txt_f="20162">], to determine whether a one-sided 80% confidence interval would exclude a 10% increase in the primary outcome (ELDQOL).</offsets></p></list-item><list-item><p><offsets xml_i="31619" xml_f="31861" txt_i="20163" txt_f="20405">The frequency of use of the Books Beyond Words intervention, and other sources of information before and after randomization, and the extent to which use of the Books Beyond Words booklet influences outcome and other information resource use.</offsets></p></list-item></list></p><p><offsets xml_i="31891" xml_f="32246" txt_i="20407" txt_f="20762">In parallel, a health economic assessment will be undertaken. We will monitor levels of resource-use and quality of life to inform the decision as to how costs and benefits should be measured as part of a future, more definitive study. NICE guidance recommends that costs are calculated from the perspective of the NHS and Personal Social Services (PSS) [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="32279" xml_f="32281" txt_i="20762" txt_f="20764">33</offsets></xref><xref ref-type="bibr" rid="CR34"><offsets xml_i="32321" xml_f="32323" txt_i="20764" txt_f="20766">34</offsets></xref><offsets xml_i="32330" xml_f="32372" txt_i="20766" txt_f="20808">]. In line with NICE guidance, the EQ-5D [</offsets><xref ref-type="bibr" rid="CR35"><offsets xml_i="32405" xml_f="32407" txt_i="20808" txt_f="20810">35</offsets></xref><offsets xml_i="32414" xml_f="32614" txt_i="20810" txt_f="21010">] will be used to assess the effectiveness of each option. This will enable the quality-adjusted life year gain to be estimated. All analyses will be reported according to relevant CONSORT standards [</offsets><xref ref-type="bibr" rid="CR36"><offsets xml_i="32647" xml_f="32649" txt_i="21010" txt_f="21012">36</offsets></xref><offsets xml_i="32656" xml_f="32658" txt_i="21012" txt_f="21014">].</offsets></p></sec><sec id="Sec21"><title><offsets xml_i="32691" xml_f="32707" txt_i="21016" txt_f="21032">Qualitative data</offsets></title><p><offsets xml_i="32718" xml_f="32871" txt_i="21033" txt_f="21186">The data collected in the semi-structured interviews will be analyzed using a two-step thematic content analysis derived from descriptive phenomenology [</offsets><xref ref-type="bibr" rid="CR37"><offsets xml_i="32904" xml_f="32906" txt_i="21186" txt_f="21188">37</offsets></xref><offsets xml_i="32913" xml_f="32915" txt_i="21188" txt_f="21190">, </offsets><xref ref-type="bibr" rid="CR38"><offsets xml_i="32948" xml_f="32950" txt_i="21190" txt_f="21192">38</offsets></xref><offsets xml_i="32957" xml_f="33000" txt_i="21192" txt_f="21235">], assisted by the computer software NVivo.</offsets></p></sec></sec><sec id="Sec22"><title><offsets xml_i="33039" xml_f="33081" txt_i="21238" txt_f="21280">Sample size and feasibility of recruitment</offsets></title><p><offsets xml_i="33092" xml_f="33357" txt_i="21281" txt_f="21546">The present study aims to assess the variation in the primary outcome measure between groups from baseline to the 12-week follow-up assessment, in order to determine whether the intervention is likely to achieve a 10% increase in the participants’ quality of life [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="33390" xml_f="33392" txt_i="21546" txt_f="21548">32</offsets></xref><offsets xml_i="33399" xml_f="33971" txt_i="21548" txt_f="22117">]. This would equate to an effect size of approximately 0.4, requiring a total sample size of 174 in a full study (1-β = 0.8, α = 0.05). Based on the requirement of 9% of the total sample size in each group, this indicates a required sample size of 16 per group, and will enable the exclusion of an effect size of &lt;0. Given a potential 25% dropout rate, a sample size of 20 per group (40 participants in total) will be targeted. However, the study team, the selected study design and recruitment procedures will aim to minimize all potential dropouts whenever possible.</offsets></p><p><offsets xml_i="33978" xml_f="34545" txt_i="22118" txt_f="22685">Recent audit data indicates that there were 196 patients with epilepsy and learning disabilities registered at the Hertfordshire Partnership University NHS Foundation Trust in May 2013. A preliminary screening exercise has already been undertaken by the lead consultant psychiatrist, at each epilepsy clinic, confirming that 112 out of 196 patients meet the study’s inclusion criteria. This does not include new referrals, who will be screened for eligibility once recruitment commences. The study will therefore aim to recruit approximately 36% of eligible patients.</offsets></p></sec><sec id="Sec23"><title><offsets xml_i="34578" xml_f="34593" txt_i="22687" txt_f="22702">Confidentiality</offsets></title><p><offsets xml_i="34604" xml_f="34682" txt_i="22703" txt_f="22781">This study will be conducted in accordance with the Data Protection Act 1998 [</offsets><xref ref-type="bibr" rid="CR39"><offsets xml_i="34715" xml_f="34717" txt_i="22781" txt_f="22783">39</offsets></xref><offsets xml_i="34724" xml_f="34803" txt_i="22783" txt_f="22862">] and the guidelines of the Declaration of Helsinki 1964 (updated Tokyo 2004) [</offsets><xref ref-type="bibr" rid="CR40"><offsets xml_i="34836" xml_f="34838" txt_i="22862" txt_f="22864">40</offsets></xref><offsets xml_i="34845" xml_f="35445" txt_i="22864" txt_f="23464">]. Access to the screening and randomization log, containing patient-identifiable data, will be restricted to authorized personnel and will be password-protected. Only GCP certified investigators approved by the Trial Steering Committee will be able to access the data. A unique patient identification number will be generated by the study web-based data entry system for each new patient entered in the system by the research nurse. This ensures anonymized data. A sequential number, starting at 001, will be generated for each new patient consented and entered into the study by the research nurse.</offsets></p><p><offsets xml_i="35452" xml_f="36379" txt_i="23465" txt_f="24392">The original signed consent forms will be retained at the study site, in a locked cabinet. After all participants have been recruited, the researcher will collect baseline questionnaires from the epilepsy clinics. All case report forms and signed consent forms will be collected at the end of the study and stored in a locked cabinet at the University of Hertfordshire. Patient data relating to the study will be deleted or destroyed within three months of the end of the study. Anonymized study data will be archived by the University of Hertfordshire for five years after study completion, in line with standard research protocols. Investigators will not disclose patient data in any form to anyone not involved directly in the study. All electronic data will be stored on password-protected computers, and paper files will be stored in locked filing cabinets, both of which will be kept within electronically locked offices.</offsets></p></sec><sec id="Sec24"><title><offsets xml_i="36412" xml_f="36434" txt_i="24394" txt_f="24416">Ethical considerations</offsets></title><p><offsets xml_i="36445" xml_f="37060" txt_i="24417" txt_f="25032">This study includes people with learning disabilities who may or may not lack the capacity to consent. Whenever possible, consent will be obtained from the patient, with the carer’s involvement and advice, who will assess the participants’ capacity to take part, as required by the Mental Capacity Act. For patients who have the capacity to read or be read to and understand simple information (as determined by the carer and research nurse), an easy-read information sheet and invitation letter will be provided. These have been specifically designed according to the principles of the Mental Capacity Act (2005) [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="37093" xml_f="37095" txt_i="25032" txt_f="25034">27</offsets></xref><offsets xml_i="37102" xml_f="37995" txt_i="25034" txt_f="25927">], guidance from the Department of Health on producing easy-read information and guidance from the National Ethics Service on the design of study materials for adults without capacity. The information is paced, carefully structured, using simple language and images and with frequent references made to the carer. The easy-read consent form, invitation letter and information sheet have been reviewed by people from Hertfordshire Partnership University Foundation Trust, specializing in the development of easy-read information, and by members of our reference group, including people with learning disabilities, carers and members of the public. For patients who lack the capacity to consent, carers will be asked to complete and sign a consultee declaration form. Ethical approval for this study was granted on 28 April 2014, by the Wales Research Ethics Committee 5 (reference: 14/WA/0135).</offsets></p></sec></sec><sec id="Sec25" sec-type="discussion"><title><offsets xml_i="38056" xml_f="38066" txt_i="25930" txt_f="25940">Discussion</offsets></title><p><offsets xml_i="38077" xml_f="39319" txt_i="25941" txt_f="27183">This study is the first to assess the feasibility of undertaking a randomized controlled trial of an image-centric intervention, designed to facilitate the management of epilepsy in people with learning disabilities. The outputs of this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to determine the impact of the Books Beyond Words intervention to improve the management of epilepsy in people with learning disabilities. As advocated by NICE, The Royal College of General Practitioners and the Learning Disabilities Observatory, improving disease management and access to services of people with learning disabilities and epilepsy is essential and should become a priority in routine care. Although the feasibility study will not demonstrate whether or not Books Beyond Words interventions can achieve those goals, and provide value for money, this will be addressed by the definitive trial. The results will therefore have significant and long-lasting implications for clinical practice and service delivery, whereby Books Beyond Words interventions could become routinely embedded in the NHS, yielding significant benefits for patients, their carers and the wider population.</offsets></p><p><offsets xml_i="39326" xml_f="40348" txt_i="27184" txt_f="28206">Further, the results of the feasibility trial will be of utmost importance to patient groups and clinicians in raising awareness of emerging research in learning disabilities and epilepsy, and demonstrating the potential acceptability of this intervention. Dissemination of the results will primarily be achieved through publication in peer-reviewed scientific journals, and reports intended for people with learning disability, their carers, families and the wider lay community, disseminated through national and local patient networks, including the Making it Better Group, Inclusion East, and the British Institute of Learning Disabilities (BILD). Promoting the involvement of people with learning disabilities in research and demonstrating potential benefits will be another focus of our dissemination strategy. We will work closely with the BILD and with the Patient Involvement in Research Group to raise awareness and increase the representation of patients with learning disabilities and their carers in research.</offsets></p></sec><sec id="Sec26"><title><offsets xml_i="40381" xml_f="40393" txt_i="28208" txt_f="28220">Trial status</offsets></title><p><offsets xml_i="40404" xml_f="40537" txt_i="28221" txt_f="28354">The trial set-up phase was completed at the end of May 2014. Recruitment started on 1 July 2014 and is expected to end in March 2015.</offsets></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>BILD</term><def><p>British Institute of Learning Disabilities</p></def></def-item><def-item><term>CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term>CTU</term><def><p>Clinical Trials Unit</p></def></def-item><def-item><term>ELDQOL</term><def><p>Epilepsy and Learning Disabilities Quality of Life (scale)</p></def></def-item><def-item><term>GCP</term><def><p>Good Clinical Practice</p></def></def-item><def-item><term>ISRCTN</term><def><p>International Standard Randomized Controlled Trial Number</p></def></def-item><def-item><term>NHS</term><def><p>National Health Service</p></def></def-item><def-item><term>NICE</term><def><p>National Institute for health and Clinical Excellence</p></def></def-item><def-item><term>NCTU</term><def><p>Norwich Clinical Trials Unit</p></def></def-item><def-item><term>PSS</term><def><p>Personal Social Services</p></def></def-item><def-item><term>SQL</term><def><p>Structured Query Language</p></def></def-item><def-item><term>WIELD</term><def><p>Wordless Intervention for Epilepsy in Learning Disabilities.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>M-A D, BG, GP, AZ, KF, GB, HR, and DW participated in the design and conception of the study. M-A D, BG and LO drafted the study protocol. All authors commented on all subsequent drafts of the protocol. M-A D and LO prepared all study documents and ethics application. M-A D completed the first draft of the manuscript. All authors commented on all subsequent drafts of the manuscript. All authors read and approved the final version of the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The study team are grateful for the continued support and valuable contributions of the Patient Involvement in Research Group at the University of Hertfordshire, The Making Better Services Group, Inclusion East, the East of England Research Design Service, The Norwich Clinical Trials Unit, Books Beyond Words, and Professor Tim Gale at Hertfordshire Partnership University NHS Foundation Trust.</p><p>This study is funded by the NIHR Research for Patient Benefit program (reference number: RfPB PB-PG-0213-30042).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>E</given-names></name><name><surname>Ferini-Strambi</surname><given-names>L</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Erminio</surname><given-names>C</given-names></name><name><surname>Smirne</surname><given-names>S</given-names></name></person-group><article-title>Epilepsy in institutionalized patients with encephalopathy: clinical aspects and nosological considerations</article-title><source>Am J Ment Retard</source><year>1993</year><volume>98</volume><issue>Suppl</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8352919</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Schrojenstein Lantman De Valk</surname><given-names>HM</given-names></name><name><surname>Metsemakers</surname><given-names>JF</given-names></name><name><surname>Haveman</surname><given-names>MJ</given-names></name><name><surname>Crebolder</surname><given-names>HF</given-names></name></person-group><article-title>Health problems in people with intellectual disability in general practice: a comparative study</article-title><source>Fam Pract</source><year>2000</year><volume>17</volume><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1093/fampra/17.5.405</pub-id><pub-id pub-id-type="pmid">11021900</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Schrojenstein Lantman De Valk</surname><given-names>HM</given-names></name><name><surname>Van Den Akker</surname><given-names>M</given-names></name><name><surname>Maaskant</surname><given-names>MA</given-names></name><name><surname>Haveman</surname><given-names>MJ</given-names></name><name><surname>Urlings</surname><given-names>HF</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Crebolder</surname><given-names>HF</given-names></name></person-group><article-title>Prevalence and incidence of health problems in people with intellectual disability</article-title><source>J Intellect Disabil Res</source><year>1997</year><volume>41</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2788.1997.tb00675.x</pub-id><pub-id pub-id-type="pmid">9089458</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Schrojenstein Lantman De Valk</surname><given-names>HM</given-names></name><name><surname>Walsh</surname><given-names>PN</given-names></name></person-group><article-title>Managing health problems in people with intellectual disabilities</article-title><source>BMJ</source><year>2008</year><volume>337</volume><fpage>a2507</fpage><pub-id pub-id-type="doi">10.1136/bmj.a2507</pub-id><pub-id pub-id-type="pmid">19064601</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowley</surname><given-names>C</given-names></name><name><surname>Kerr</surname><given-names>M</given-names></name></person-group><article-title>Epilepsy and intellectual disability</article-title><source>J Intellect Disabil Res</source><year>2000</year><volume>44</volume><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2788.2000.00270.x</pub-id><pub-id pub-id-type="pmid">11079350</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>S</given-names></name><name><surname>Moran</surname><given-names>R</given-names></name><name><surname>Platt</surname><given-names>T</given-names></name><name><surname>Wood</surname><given-names>H</given-names></name><name><surname>Isaac</surname><given-names>T</given-names></name><name><surname>Dasari</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of epilepsy in adults with mental retardation and related disabilities in primary care</article-title><source>Am J Ment Retard</source><year>2005</year><volume>110</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1352/0895-8017(2005)110&lt;48:POEIAW&gt;2.0.CO;2</pub-id><pub-id pub-id-type="pmid">15568966</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrother</surname><given-names>CW</given-names></name><name><surname>Bhaumik</surname><given-names>S</given-names></name><name><surname>Thorp</surname><given-names>CF</given-names></name><name><surname>Hauck</surname><given-names>A</given-names></name><name><surname>Branford</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>JM</given-names></name></person-group><article-title>Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications</article-title><source>Seizure</source><year>2006</year><volume>15</volume><fpage>376</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.seizure.2006.04.002</pub-id><pub-id pub-id-type="pmid">16782360</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CL</given-names></name><name><surname>Baxter</surname><given-names>H</given-names></name><name><surname>Kerr</surname><given-names>MP</given-names></name></person-group><article-title>Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability</article-title><source>Am J Ment Retard</source><year>2003</year><volume>108</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1352/0895-8017(2003)108&lt;293:POEAAH&gt;2.0.CO;2</pub-id><pub-id pub-id-type="pmid">12901705</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadwick</surname><given-names>D</given-names></name></person-group><article-title>Epilepsy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1994</year><volume>57</volume><fpage>264</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1136/jnnp.57.3.264</pub-id><pub-id pub-id-type="pmid">8158172</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">World Health Organization: <bold>Epilepsy.</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs999/en/">http://www.who.int/mediacentre/factsheets/fs999/en/</ext-link>]</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beavis</surname><given-names>J</given-names></name><name><surname>Kerr</surname><given-names>M</given-names></name><name><surname>Marson</surname><given-names>AG</given-names></name></person-group><article-title>Pharmacological interventions for epilepsy in people with intellectual disabilities</article-title><source>Cochrane Database Syst Rev</source><year>2007</year></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branford</surname><given-names>D</given-names></name><name><surname>Bhaumik</surname><given-names>S</given-names></name><name><surname>Duncan</surname><given-names>F</given-names></name></person-group><article-title>Epilepsy in adults with learning disabilities</article-title><source>Seizure</source><year>1998</year><volume>7</volume><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/S1059-1311(98)80005-8</pub-id><pub-id pub-id-type="pmid">9888491</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branford</surname><given-names>D</given-names></name><name><surname>Bhaumik</surname><given-names>S</given-names></name><name><surname>Duncan</surname><given-names>F</given-names></name><name><surname>Collacott</surname><given-names>RA</given-names></name></person-group><article-title>A follow-up study of adults with learning disabilities and epilepsy</article-title><source>Seizure</source><year>1998</year><volume>7</volume><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/S1059-1311(98)80004-6</pub-id><pub-id pub-id-type="pmid">9888490</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>M</given-names></name></person-group><article-title>Epilepsy and learning disabilities</article-title><source>Epilepsy: From Cell to Community, a Practical Guide to Epilepsy</source><year>2007</year><edition>11</edition><publisher-loc>London</publisher-loc><publisher-name>Pat Talbot, Geoff Astbury, Tom Mason, SAGE Publications</publisher-name></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>MJ</given-names></name></person-group><article-title>Antiepileptic drugs, clinical trials, and the marketplace</article-title><source>Lancet</source><year>1996</year><volume>347</volume><fpage>777</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)90863-6</pub-id><pub-id pub-id-type="pmid">8622329</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannah</surname><given-names>JA</given-names></name><name><surname>Brodie</surname><given-names>MJ</given-names></name></person-group><article-title>Epilepsy and learning disabilities–a challenge for the next millennium?</article-title><source>Seizure</source><year>1998</year><volume>7</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/S1059-1311(98)90002-4</pub-id><pub-id pub-id-type="pmid">9548220</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Association of the Scientific Study of Intellectual Disabilities (IASSID)</collab></person-group><article-title>Clinical guidelines for the management of epilepsy in adults with an intellectual disability</article-title><source>Seizure</source><year>2001</year><volume>10</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1053/seiz.2001.0528</pub-id><pub-id pub-id-type="pmid">11700992</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>M</given-names></name><name><surname>Bowley</surname><given-names>C</given-names></name></person-group><article-title>Multidisciplinary and multiagency contributions to care for those with learning disability who have epilepsy</article-title><source>Epilepsia</source><year>2001</year><volume>42</volume><issue>Suppl 1</issue><fpage>55</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1046/j.1528-1157.2001.00519.x</pub-id><pub-id pub-id-type="pmid">11422361</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>M</given-names></name><name><surname>Bowley</surname><given-names>C</given-names></name></person-group><article-title>Evidence-based prescribing in adults with learning disability and epilepsy</article-title><source>Epilepsia</source><year>2001</year><volume>42</volume><issue>Suppl 1</issue><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1046/j.1528-1157.2001.00515.x</pub-id><pub-id pub-id-type="pmid">11422357</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Blarikom</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>IY</given-names></name><name><surname>Aldenkamp</surname><given-names>AP</given-names></name><name><surname>van Gennep</surname><given-names>ATG</given-names></name></person-group><article-title>Epilepsy, intellectual disability, and living environment: a critical review</article-title><source>Epilepsy Behav</source><year>2006</year><volume>9</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2006.04.001</pub-id><pub-id pub-id-type="pmid">16714148</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Ayub</surname><given-names>M</given-names></name></person-group><source>How People With Learning Disabilities Die</source><year>2010</year><publisher-loc>Durham</publisher-loc><publisher-name>Improving Health and Lives: Learning Disabilities Observatory</publisher-name></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockerell</surname><given-names>OC</given-names></name><name><surname>Hart</surname><given-names>YM</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name><name><surname>Shorvon</surname><given-names>SD</given-names></name></person-group><article-title>The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies</article-title><source>Epilepsy Res</source><year>1994</year><volume>18</volume><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/0920-1211(94)90045-0</pub-id><pub-id pub-id-type="pmid">7805646</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennington</surname><given-names>M</given-names></name><name><surname>Prince</surname><given-names>E</given-names></name><name><surname>Bateman</surname><given-names>N</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Croudace</surname><given-names>TJ</given-names></name><name><surname>Redley</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Ring</surname><given-names>H</given-names></name></person-group><article-title>Factors influencing the costs of epilepsy in adults with an intellectual disability</article-title><source>Seizure</source><year>2012</year><volume>21</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.seizure.2011.12.012</pub-id><pub-id pub-id-type="pmid">22285238</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Improving Health and Lives: Learning Disabilities Observatory</collab></person-group><source>Improving the health and wellbeing of people with learning disabilities: an evidence-based commissioning guide for clinical commissioning groups (CCGs)</source><year>2012</year><publisher-loc>Durham</publisher-loc><publisher-name>Improving Health and Lives: Learning Disabilities Observatory</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>E</given-names></name><name><surname>Baines</surname><given-names>S</given-names></name></person-group><source>Health Inequalities and People with Learning Disabilities</source><year>2010</year><publisher-loc>Durham</publisher-loc><publisher-name>Improving Health and Lives: Learning Disabilities Observatory</publisher-name></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group><source>The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care. NICE Clinical Guideline 137</source><year>2012</year><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other"><bold>Mental Capacity Act 2005</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.legislation.gov.uk/ukpga/2005/9/contents">http://www.legislation.gov.uk/ukpga/2005/9/contents</ext-link>]</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other"><bold>Books Beyond Words</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.booksbeyondwords.co.uk/">http://www.booksbeyondwords.co.uk/</ext-link>]</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>GA</given-names></name><name><surname>Jacoby</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>DF</given-names></name><name><surname>Dewey</surname><given-names>ME</given-names></name><name><surname>Chadwick</surname><given-names>DW</given-names></name></person-group><article-title>Development of a novel scale to assess life fulfillment as part of the further refinement of a quality-of-life model for epilepsy</article-title><source>Epilepsia</source><year>1994</year><volume>35</volume><fpage>591</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1994.tb02479.x</pub-id><pub-id pub-id-type="pmid">8026405</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Appleton</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>GA</given-names></name><name><surname>Jacoby</surname><given-names>A</given-names></name></person-group><article-title>The development and validation of the epilepsy and learning disabilities quality of life (ELDQOL) scale</article-title><source>Epilepsy Behav</source><year>2007</year><volume>10</volume><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2006.10.010</pub-id><pub-id pub-id-type="pmid">17126607</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdman</surname><given-names>M</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Janssen</surname><given-names>M</given-names></name><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name><name><surname>Bonsel</surname><given-names>G</given-names></name><name><surname>Badia</surname><given-names>X</given-names></name></person-group><article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L)</article-title><source>Qual Life Res</source><year>2011</year><volume>20</volume><fpage>1727</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id><pub-id pub-id-type="pmid">21479777</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocks</surname><given-names>K</given-names></name><name><surname>Torgerson</surname><given-names>DJ</given-names></name></person-group><article-title>Sample size calculations for pilot randomized trials: a confidence interval approach</article-title><source>J Clin Epidemiol</source><year>2013</year><volume>66</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2012.09.002</pub-id><pub-id pub-id-type="pmid">23195919</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Clinical Excellence</collab></person-group><source>NICE Guide to the Methods of Technology Appraisal</source><year>2008</year><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>L</given-names></name></person-group><source>Unit Costs of Health and Social Care 2011</source><year>2011</year></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>R</given-names></name></person-group><article-title>EuroQol: the current state of play</article-title><source>Health Policy</source><year>1996</year><volume>37</volume><fpage>53</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/0168-8510(96)00822-6</pub-id><pub-id pub-id-type="pmid">10158943</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>c332</fpage><pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id><pub-id pub-id-type="pmid">20332509</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Denzin</surname><given-names>NK</given-names></name><name><surname>Lincoln</surname><given-names>YS</given-names></name></person-group><source>Handbook of Qualitative Research</source><year>2000</year><edition>2</edition><publisher-loc>Thousand Oaks</publisher-loc><publisher-name>Sage Publications</publisher-name></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>I</given-names></name></person-group><source>Qualitative Research in Health Care</source><year>2005</year><publisher-loc>Maidenhead</publisher-loc><publisher-name>Open University Press</publisher-name></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other"><bold>Data Protection Act 1998</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.legislation.gov.uk/ukpga/1998/29/contents">http://www.legislation.gov.uk/ukpga/1998/29/contents</ext-link>]</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Medical Association</collab></person-group><article-title>Amended by the 59th WMA General Assembly, Seoul, Korea, 2008</article-title><source>WMA Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects</source><year>2008</year><publisher-loc>Ferney-Voltaire, France</publisher-loc><publisher-name>WMA</publisher-name></element-citation></ref></ref-list></back></article>